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Factor XI (FXI) deficiency is a rare autosomal recessive coagulation disorder most commonly found in Ashkenazi and Iraqi Jews, but 
it is also found in other ethnic groups. It is a trauma or surgery-related bleeding disorder, but spontaneous bleeding is rarely seen. 
The clinical manifestation of bleeding in FXI deficiency cases is variable and seems to poorly correlate with plasma FXI levels. The 
molecular pathology of FXI deficiency is mutation in the F11 gene on the chromosome band 4q35. We report a novel mutation of 
the F11 gene in an 18-year-old asymptomatic Korean woman with mild FXI deficiency. Pre-operative laboratory screen tests for li-
poma on her back revealed slightly prolonged activated partial thromboplastin time (45.2 sec; reference range, 23.2-39.4 sec). Her 
FXI activity (35%) was slightly lower than the normal FXI activity (reference range, 50-150%). Direct sequence analysis of the F11 
gene revealed a heterozygous A to G substitution in nucleotide 1517 (c.1517A>G) of exon 13, resulting in the substitution of as-
partic acid with glycine in codon 506 (p.Asp506Gly). To the best of our knowledge, the Asp506Gly is a novel missense mutation, 
and this is the first genetically confirmed case of mild FXI deficiency in Korea. 
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INTRODUCTION
Factor XI (FXI) is a zymogen of the serine protease FXIa, 
which is an essential component in the intrinsic blood co-
agulation cascade, and functions through the activation of 
factor IX [1, 2]. FXI is produced in the liver and circulates 
in plasma as a disulfide-linked homodimer involved in non-
covalent interaction with high-molecular-weight kininogen 
(HK) [3]. Each FXI monomer (80 kDa) is made up of 4 N-
terminal apple domains (A1-A4) and a C-terminal trypsin 
like catalytic domain [4]. 
The human FXI gene (F11), which encodes the FXI pro-
tein, is located on the long arm of chromosome 4 (4q35) with 
a genome size of approximately 23 kb. The gene consists of 
15 exons and 14 introns. Exon 1 corresponds to the 5´-un-
translated region, exon 2 encodes the signal peptide, and 
exons 3-15 encode the mature FXI molecule [5].
Hereditary FXI deficiency (also known as hemophilia C) 
was first described as a hemophilia-like syndrome by Rosen-
thal et al. [6] in 1953. It is inherited as an autosomal recessive 
trait that may arise because of a wide range of mutations, in-
cluding missense, nonsense, splice-site, insertion, and dele-
tion mutations, within the F11 gene [4]. 
We report a case of a Korean woman with mild factor XI 
deficiency who was harboring a novel heterozygous muta-
tion in the F11 gene. Only 8 cases of FXI deficiency have 
been reported in Korea, of which only 1 case has been ge-
netically confirmed to be a case of severe FXI deficiency [7-
11]. To the best of our knowledge, this is the first genetically 
confirmed case of mild FXI deficiency in Korea. 
CASE REPORT
1. Clinical features
An 18-year-old Korean woman visited the outpatient clinic 
for resection of a lipoma on her back. No apparent abnor-
mal bleeding tendency was noted in her personal or familial Lee JH, et al.  •  A novel F11 mutation
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history. Preoperative laboratory screen tests revealed that 
the patient had prolonged activated partial thromboplastin 
time (aPTT, 45.2 sec; reference range, 23.2-39.4 sec; Syn-
thASil APTT; Instrumentation Laboratory, Bedford, MA, 
USA), normal prothrombin time (PT, 12.0 sec; reference 
range, 10.4-13.3 sec), and normal liver function. The pro-
longed aPTT was corrected by mixing the patient’s plasma 
sample with the normal plasma in the ratio 1:1, and the re-
sults of the tests for lupus anticoagulants were negative. Co-
agulation factor assays showed normal levels of factor VIII 
(FVIII, 69%; reference range, 60-150%), and factor IX (FIX, 
75%; reference range, 60-150%), but showed slightly de-
creased FXI activity (35%; reference range, 50-150%; STA-
Deficient XI; Diagno  stica Stago, Asnieres, France). 
2. Molecular genetic study
The patient’s peripheral blood sample was obtained after 
receiving her informed consent. Genomic DNA was isolated 
from peripheral whole blood leukocytes by using the Wiz-
ard Genomic DNA purification kit (Promega, Madison, WI, 
USA) by following the manufacturer’s instructions. Each 
exon of the F11 gene and its flanking intronic sequences 
were amplified using PCR with primers (available upon re-
quest) designed by the authors and a thermal cycler (Model 
9700; Applied Biosystems, Foster City, CA, USA). Direct 
sequencing was performed with the same primer set and 
the BigDye Terminator Cycle Sequencing Ready Reaction 
kit (Applied Biosystems, Rotkreuz, Switzerland) by using 
the ABI Prism 3100 genetic analyzer (Applied Biosystems). 
The patient sequences were compared with reference se-
quences (GenBank accession number, NM_000128.3) by 
using the Sequencher software (Gene Codes Corporation, 
Ann Arbor, MI, USA) to identify any sequence variation. 
The guidelines of the Human Genome Variation Society 
(HGVS) were used to describe the sequence variations of 
DNA and protein. An amino acid variation was detected in 
exon 13 of F11 in the heterozygous condition. An A to G 
substitution at the nucleotide position 1517 (c.1517A>G) 
resulted in the replacement of aspartic acid with glycine at 
codon 506 (Asp506Gly) (Fig. 1). We conducted a control 
study with exon 13-targeted sequence analyses in 100 con-
trol chromosomes of 50 individuals of Korean descent with 
validated normal FXI activities since our literature search 
and search of the FXI deficiency mutation database [12] re-
vealed Asp506Gly to be a novel variation. The frequency of 
the variation was 0%. Thus, Asp506Gly was confirmed to 
be a novel mutation. 
3. Bioinformatics and structural analyses 





Fig. 1. Direct sequence analysis of the F11 gene. A heterozygous missense mutation [red arrow, c.1517A>G (p.Asp506Gly)] was detected in exon 13.
Fig. 2. Interaction of Asp506 with Arg202 located in the A3 domain. Hydro-
gen-bonding interaction between these residues is indicated by a black dot-
ted line.292     www.kjlm.org
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using the ConSurf web server revealed an evolutionary con-
servation is score 4. Functional prediction of the consequen-
ces of Asp506Gly was performed using bioinformatics pro-
grams Sorting Intolerant from Tolerant (SIFT) and Poly-
morphism Phenotyping (PolyPhen) [13, 14]. The results 
obtained were “tolerated” and “possibly damaging”, respec-
tively. 
A crystal structure of the full-length form of FXI has been 
reported (PDB code: 2F83) [15]. We performed structural 
analysis to predict the functional role of Asp506 by using 
the PyMOL program (http://www.pymol/org/). In the crys-
tal structure, the Asp506 residue in the C-terminal catalytic 
domain interacts with Arg202 in the A3 domain by form-
ing a hydrogen bond (Fig. 2). The distance between the car-
boxylate of Asp506 and the guanidinium of Arg202 is 2.6 Å. 
The substitution of aspartic acid with glycine completely 
disrupts the hydrogen-bonding interaction with Arg202. 
This disruption may lead to a conformational change in the 
A3 domain.
DISCUSSION
Hereditary FXI deficiency is a common coagulation dis-
order in Ashkenazi and Iraqi Jews with a heterozygote fre-
quency of 8% and 3.3%, respectively; however, it is very rare  ly 
seen in other ethnic groups, with a frequency of 1:1,000,000 
[16]. Patients with FXI deficiency show mutations in the F11 
gene encoding FXI. Type II (Glu117X) and type III (Phe-
283Leu) mutations are particularly prevalent in the Jewish 
population, and these 2 mutations account for approxima-
tely 95% of F11 mutations among the Jews [17-19]. How-
ever, a variety of mutations have been reported in other eth-
nic groups, with those prevalent among Ashkenazi and Iraqi 
Jews accounting for only a small percentage of the total po-
pulation of disease alleles [20, 21]. Currently, the FXI defi-
ciency mutation database contains information on 192 dis-
ease-causing mutations of the F11 gene, which was obtained 
from 487 patients with FXI deficiency reported in the litera-
ture [12].
Patients with FXI deficiency show wide variation in the 
manifestation of bleeding symptoms, and these manifesta-
tions are largely affected by the genotype and the site of in-
jury. Patients with homozygous mutations usually have se-
vere FXI deficiency (FXI activity <15%), whereas those with 
heterozygous mutations have mild/partial FXI deficiency 
(FXI activity, 20-50%) [22]. However, unlike the findings in 
hemophilia A and B, spontaneous bleeding is rarely seen 
even in patients with severe FXI deficiency. The common 
presentation of severe FXI deficiency is injury- or surgery-
related bleeding, especially when the trauma involves ana-
tomical sites with high fibrinolytic activity, such as the oral 
or nasal cavities, the prostate, and the uterus. In patients with 
heterozygous mutations, the bleeding risk has not been con-
clusively determined and is not well predicted by plasma FXI 
level [23]. 
In Korea, hereditary FXI deficiency is rare, and only 8 
cases have been reported [7-11]. A history of spontaneous 
bleeding has not been reported even in patients with severe 
deficiency, except in 1 case with intermittent nasal bleeding, 
which was easily controlled. In most of the cases, the diag-
nosis of FXI deficiency was made on the basis of coagulation 
test results without molecular genetic study. Only 1 case, in 
which severe deficiency was observed due to compound 
heterozygous mutations (Val498Met and Tyr503ValfsX32) 
of the F11 gene, has been genetically confirmed to date [11]. 
The patient showed no spontaneous or postoperative bleed-
ing despite the severely decreased FXI activity (1%). Our 
patient is the second genetically confirmed case of FXI defi-
ciency and the first genetically confirmed case of mild FXI 
deficiency in Korea. In this patient, a slightly prolonged aPTT 
of 45.2 sec was accidentally detected during preoperative 
scre  ening, and the patient had no personal history of bleed-
ing symptoms. Further coagulation tests and molecular stu-
dies revealed that she had mild FXI deficiency with an FXI 
coagulant activity (FXI:C) of 35% because of a heterozy-
gous novel missense mutation Asp506Gly in exon 13 of the 
F11 gene, which encodes the catalytic domain of FXI. The 
results of bioinformatics analysis predicted that Asp506Gly 
is tolerated or may show damaging effects on FXI function 
[14, 15]. Structural analysis shows that this mutation dis-
rupts the hydrogen-bonding interaction with Arg202 on 
the A3 domain, which is involved in binding interactions 
with the substrate FIX and is therefore required for the acti-
vation of this substrate [24]. Thus, the mutation may cause 
a conformational change in the A3 domain, consequently 
reducing the activity of the FXI protein. 
Management of mild/partial FXI deficiency is difficult 
because of the variability and unpredictability of the bleed-
ing tendency [23, 25]. Prophylactic treatment is generally 
not required for patients who do not show hemostatic ab-
normalities. However, prophylactic treatment with desmo-
pressin could be an option for patients with a history of blee-
ding [21]. Coagulation factor concentrates may be required 
for major surgery [23]. Our patient has not undergone an 
operation for the resection of the lipoma on her back; there-
fore, we need to follow up her clinical course. 
In conclusion, we report a novel missense mutation in a 
catalytic domain of the FXI protein. The Asp506Gly muta-Lee JH, et al.  •  A novel F11 mutation
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tion is associated with mild FXI deficiency and did not cause 
spontaneous bleeding in this case. This is the first report on 
a genetically confirmed case of mild FXI deficiency in Ko-
rea. Few genetically confirmed cases have been reported to 
date. Additional reports on the relation between coagula-
tion and the FXI deficiency and molecular studies on FXI 
deficiency are needed to facilitate clinical decision-making. 
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